- General info
- Available languages
- Background story
ITC New Baskerville® font family
Designed by John Quaranda in 1978 and John Baskerville in 1706-1775
Up to 8 Typefaces / 1 Value Packs
Supports at least 33 languages (Pro / OT CFF)
Available licenses for all styles:
Supports up to 74 languages.
Please select a format to view the available languages:
Supports up to 16 OpenType features.
Please select a format to view the available OpenType features:
John Baskerville (1706-1775) was an accomplished writing master and printer from Birmingham, England. He was the designer of several types, punchcut by John Handy, which are the basis for the fonts that bear the name Baskerville today. The excellent quality of his printing influenced such famous printers as Didot in France and Bodoni in Italy. Though he was known internationally as an innovator of technique and style, his high standards for paper and ink quality made it difficult for him to compete with local commercial printers. However, his fellow Englishmen imitated his types, and in 1768, Isaac Moore punchcut a version of Baskerville's letterforms for the Fry Foundry. Baskerville produced a masterpiece folio Bible for Cambridge University, and today, his types are considered to be fine representations of eighteenth century rationalism and neoclassicism. Legible and eminently dignified, Baskerville makes an excellent text typeface; and its sharp, high-contrast forms make it suitable for elegant advertising pieces as well.
The Linotype portfolio offers many versions of this design:
ITC New Baskerville® was designed by John Quaranda in 1978.
Baskerville Cyrillic was designed by the Linotype Design Studio.
Baskerville Greek was designed by Matthew Carter in 1978.
Baskerville™ Classico was designed by Franko Luin in 1995."
Download a free trial
Use this font in your own documents with a free 5 minute trial through SkyFonts. Trials are for evaluation purposes only. Learn more.
This font is currently not available.
You already tried this font within the last 24 hours or you may have exceeded your daily allowance of trials. Learn more.